Avaleht › Burkitti lümfoom › Illinois
Burkitti lümfoom kliinilised uuringud osariigis Illinois
14 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Illinois.
Linnad osariigis Illinois
Ametlik uuringutekst (inglise keeles)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- ja veel 4
VärbamineFaas 2
366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- ja veel 7
VärbamineFaas 3
Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693Blinatumomab Consolidation in Real World
- Northwestern University, Chicago
- The University of Chicago, Chicago
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. okt 2026 · NCT07117136Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- ja veel 9
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- ja veel 3
VärbamineFaas 2
365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- ja veel 2
VärbamineFaas 2
Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- ja veel 5
VärbamineFaas 3
365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
VärbamineFaas 2
Vanused 7–25 · Kõik sood · Uuendatud 19. aug 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Chicago
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT06137118Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 13. juuli 2026 · NCT07109219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
VärbamineFaas 2
Vanused 18–54 · Kõik sood · Uuendatud 17. märts 2026 · NCT06918431ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. nov 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Chicago, Chicago
VärbamineFaas 1/2
Vanused 15–50 · Kõik sood · Uuendatud 9. sept 2025 · NCT04150497Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Värbamine
Vanused 18–50 · Kõik sood · Uuendatud 19. juuni 2025 · NCT06785324Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.